medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2007; 6 (3)


MDR3 mutations associated with intrahepatic and gallbladder cholesterol cholelithiasis: an update

Mbongo-Kama E, Harnois F, Mennecier D, Leclercq E, Burnat P, Ceppa F

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 143-149
Archivo PDF: 344.74 Kb.


RESUMEN

No tiene resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Boland LL, Folsom AR, Rosamond WD. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease: a prospective study. Ann Epidemiol 2002; 12: 131-40.

  2. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120: 1459-67.

  3. Kano M, Shoda J, Sumakazi R, Oda K, Nimura Y, Tanaka N, et al. Mutations identified in the human multidrug resistance P-glycoprotein (ABCB4) gene in patients with primary hepatolithiasis. Hepatol Res 2004; 29: 160-6.

  4. Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007; 2: 29 [Epub ahead of print].

  5. Weiss KM, Ferrell RE, Hanis CL, Styne PN. Genetics and epidemiology of gallbladder disease in New World native peoples. Am J Hum Genet 1984; 36: 1259-78.

  6. Wang DO, Carey MC. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing systems. J Lipid Res 1996; 37: 606-30.

  7. Carey MC, Lamont JT. Cholesterol gallstone formation. Physical-chemistry of bile and biliary lipid secretion. Prog Liver Dis 1992; 10: 139-63.

  8. Ortiz D, Arias IM. MDR3 Mutations: a Glimpse into Pandora’s box and the future of canalicular pathophysiology. Gastroenterology 2001; 120: 1549-51.

  9. Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9: 1209-17.

  10. De Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998; 95: 282-7.

  11. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210-1.

  12. Eloranta ML, Heiskanen JT, Hiltunen MJ, Mannermaa AJ, Punnonen KR, Heinonen ST. Multidrug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecol Reprod Biol 2002; 104: 109-12.

  13. Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40: e32.

  14. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.

  15. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131: 624-9.

  16. Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006; 23: 1649-53.

  17. Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T, Van de Vondel P, et al. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Pharmacogenet Genomics 2007; 17: 47-60.

  18. Jacquemin E, de Vree JML, Cresteil D, Sokal E, Sturm E, Dumont M, Scheffer GL, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58.

  19. Jacquemin E. Progressive familial intrahepatic cholestasis: genetic basis and treatment. Clin Liver Dis 2000; 4: 753-63.

  20. Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, Jeng YM, et al. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr Res 2001; 50: 50-5.

  21. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007; 27: 77-98.

  22. Arrese M. Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. Ann Hepatol 2006; 5: 216-8.

  23. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Hepatology 2007; 45: 150-8.

  24. VanBerge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK. Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease. Scand J Gastroenterol Suppl 2004; 241: 60-9.




2020     |     www.medigraphic.com